Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Charlene Belanger is active.

Publication


Featured researches published by Charlene Belanger.


American Journal of Obstetrics and Gynecology | 1981

Early menopause and the risk of myocardial infarction.

Lynn Rosenberg; Charles H. Hennekens; Bernard Rosner; Charlene Belanger; Kenneth J. Rothman; Frank E. Speizer

We evaluated the relation between age at menopause and the risk of nonfatal myocardial infarction (MI) among 121,964 nurses who responded to a mail questionnaire. Of 279 women who reported having been hospitalized for MI, 123 (44%) were postmenopausal (i.e., no longer menstruating) at the time of hospitalization, compared with 1,859 (33%) of 5,580 age-matched control subjects. Among women who became menopausal because of bilateral oophorectomy, the estimated relative risk of MI increased with decreasing age at menopause, and women who underwent bilateral oophorectomy before age 35 were estimated to have a risk of hospitalization for MI approximately 7.2 times (95% confidence interval, 4.5 to 11.4) that of premenopausal women. Hysterectomy without the removal of both ovaries was only weakly associated with an increased risk. The data support the hypothesis that premature cessation of ovarian function increases the risk of nonfatal MI.


Circulation | 1981

Use of postmenopausal hormones and risk of myocardial infarction.

Chris Bain; Walter C. Willett; C H Hennekens; Bernard Rosner; Charlene Belanger; Frank E. Speizer

Information was collected by mail survey about myocardial infarction (MI), use of female hormones after menopause, and coronary risk factors from 121,964 registered nurses ages 30-55 years. One hundred twenty-three women with a known type of prior menopause reported hospitalization for MI. Overall, use of female hormones by these women was very similar to that of control women matched for age and type of menopause. Compared with nonusers, the relative risk (RR) for women who had ever taken female hormones was 0,9 (95% confidence limits 0.6-1.2), and for current users the RR was 0.7 (0.5-1.1). For women with bilateral oophorectomy, the RR for current users was 0.4 (0.20.8). These data imply that, at present, a decision to prescribe postmenopausal hormones should be based primarily on weighing possible benefits from the relief of menopausal symptoms against known or suspected risks of other diseases, particularly uterine cancer in women with an intact uterus.


American Journal of Public Health | 1980

Characteristics of respondents and non-respondents to a mailed questionnaire.

J Barton; Chris Bain; C H Hennekens; Bernard Rosner; Charlene Belanger; A Roth; Frank E. Speizer

In establishing a cohort of U.S. nurses, an assessment of response bias was made comparing respondents and non-respondents with regard to age, education, state of residence, employment status, field of employment, and major specialty. Overall, the 122,328 respondents (69.7 per cent) and 43,222 non-respondents were quite similar. Together with the reasonable response rate in a homogeneous population, this suggests that estimation of exposure-disease associations is unlikely to be affected by major bias due to non-response.


The Lancet | 1979

Use of permanent hair dyes and cancer among registered nurses.

C H Hennekens; Frank E. Speizer; Bernard Rosner; ChristopherJ. Bain; Charlene Belanger; Richard Peto

Abstract A survey of 120 557 married, female, registered U.S. nurses, aged 30 to 55 years, carried out in 1976, showed that 38 459 (31·9%) had at some time used hair dyes, and 3548 (2·9%) had had cancer. For all cancers combined, the risk ratio (R.R.) for the development of cancer among women who had used hair dyes at any time, compared with those who had never used them, was 1·10 (P=0·02). When cancers were subdivided by anatomical site into 16 main groups, only those of the cervix uteri (R.R.=1·44, P


Cancer | 1984

A case-control study of risk indicators among women with premenopausal and early postmenopausal breast cancer.

Robert J. Lipnick; Frank E. Speizer; Chris Bain; Walter C. Willett; Bernard Rosner; Meir J. Stampfer; Charlene Belanger; Charles H. Hennekens

Among 714 premenopausal and 130 postmenopausal breast cancer cases matched with 8440 controls for age in years and menopausal status, risk indicators for breast cancer were similar, although most associations were stronger in the premenopausal women. Compared with nulliparous women, the relative risk (RR) for those with first birth before age 25 years was 0.7 (95% confidence limits [CL] from 0.5 to 0.9) among premenopausal women, and 0.7 (0.4–1.4) for postmenopausal women. In the premenopausal cases, a history of breast cancer in a sister gave a RR of 3.0 (2.1–4.1) and in a mother 1.9 (1.4–2.5), whereas for the postmenopausal women the RRs were 1.4 (0.6–3.1) and 13 (0.6–2.6), respectively. Fibrocystic breast disease was also a significant predictor of subsequent breast cancer in the premenopausal and postmenopausal women. In relation to women having a single birth, premenopausal women with six or more births had a risk of breast cancer of 0.6 (0.4–1.0), which was present even after adjustment for age at first birth.


American Journal of Nursing | 1978

The Nursesʼ Health Study

Charlene Belanger; Charles H. Hennekens; Bernard Rosner; Frank E. Speizer

RESULTS — During 2.22 million person-years of follow-up, 1,398 women had a hip fracture. Compared with women without diabetes, the age-adjusted relative risk (RRs) of hip fracture was 7.1 (95% CI 4.4–11.4) for women with type 1 diabetes and 1.7 (1.4–2.0) for those with type 2 diabetes. After further adjustment for BMI, smoking, physical activity, menopausal status, daily intake of calcium, vitamin D, protein, and postmenopausal hormone use, the multivariate RR of incident hip fracture in individuals with type 1 diabetes compared with individuals without diabetes was 6.4 (3.9–10.3) and with type 2 diabetes was 2.2 (1.8–2.7). The RRs increased with longer duration of type 2 diabetes (3.1 [2.3–4.0] for 12 years compared with no diabetes, P for trend 0.001) and ever use of insulin.


American Journal of Nursing | 1978

The Nurses' Health Study

Charlene Belanger; Charles H. Hennekens; Bernard Rosner; Frank E. Speizer


American Journal of Epidemiology | 1980

FAMILY HISTORY OF BREAST CANCER AS A RISK INDICATOR FOR THE DISEASE

Chris Bain; Frank E. Speizer; Bernard Rosner; Charlene Belanger; Charles H. Hennekens


American Journal of Epidemiology | 1980

ORAL CONTRACEPTIVE USE IN RELATION TO NONFATAL MYOCARDIAL INFARCTION

Lynn Rosenberg; Charles H. Hennekens; Bernard Rosner; Charlene Belanger; Kenneth J. Rothman; Frank E. Speizer


Journal of the National Cancer Institute | 1982

Oral contraceptive use and malignant melanoma.

Chris Bain; Charles H. Hennekens; Frank E. Speizer; Bernard Rosner; Walter C. Willett; Charlene Belanger

Collaboration


Dive into the Charlene Belanger's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Frank E. Speizer

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Chris Bain

QIMR Berghofer Medical Research Institute

View shared research outputs
Top Co-Authors

Avatar

Chris Bain

QIMR Berghofer Medical Research Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge